Literature DB >> 6853710

Pyridoxal phosphate as an antisickling agent in vitro.

J A Kark, P G Tarassoff, R Bongiovanni.   

Abstract

Although pyridoxal phosphate is known to inhibit gelation of purified hemoglobin S, antisickling activity has never been demonstrated for intact erythrocytes. We incubated washed erythrocytes at 37 degrees C either in buffer alone, or with added pyridoxal phosphate or pyridoxal, washed these cells, suspended them in untreated buffer, and compared the percent modified hemoglobin, the oxygen affinity, and the extent of sickling under hypoxia. Pyridoxal phosphate modified intracellular hemoglobin more slowly than pyridoxal. Pyridoxal phosphate lowered the oxygen affinity of normal cells, but had no effect on oxygen binding by sickle cells. Pyridoxal increased the oxygen affinity of normal and sickle erythrocytes equally. Pyridoxal phosphate significantly inhibited sickling of sickle or sickle trait erythrocytes (P less than 0.001). Inhibition of sickling by pyridoxal phosphate was largely independent of oxygen binding; whereas inhibition of sickling by pyridoxal was almost entirely dependent on increased oxygen binding. Although pyridoxal phosphate and pyridoxal both inhibit sickling by modification of hemoglobin S, they differ in the kinetics of whole cell modification, the effect on oxygen affinity of intact cells, and the mechanism of action of the antisickling activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6853710      PMCID: PMC436982          DOI: 10.1172/jci110871

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  Effect of pyridoxal 5'-phosphate on the oxygen affinity of human erythrocytes.

Authors:  N Maeda; K Takahashi; K Aono; T Shiga
Journal:  Br J Haematol       Date:  1976-11       Impact factor: 6.998

2.  Studies on the mechanism of action of cyanate in sickle cell disease. Oxygen affinity and gelling properties of hemoglobin S carbamylated on specific chains.

Authors:  A M Nigen; N Njikam; C K Lee; J M Manning
Journal:  J Biol Chem       Date:  1974-10-25       Impact factor: 5.157

3.  Chemical modifications that inhibit gelation of sickle hemoglobin.

Authors:  R Benesch; R E Benesch; S Yung
Journal:  Proc Natl Acad Sci U S A       Date:  1974-04       Impact factor: 11.205

Review 4.  Clinical evaluation of cyanate in sickle cell anemia.

Authors:  D R Harkness; S Roth
Journal:  Prog Hematol       Date:  1975

5.  Structure of human deoxyhemoglobin specifically modified with pyridoxal compounds.

Authors:  A Arnone; R E Benesch; R Benesch
Journal:  J Mol Biol       Date:  1977-10-05       Impact factor: 5.469

6.  Schiff base adducts of hemoglobin. Modifications that inhibit erythrocyte sickling.

Authors:  R H Zaugg; J A Walder; I M Klotz
Journal:  J Biol Chem       Date:  1977-12-10       Impact factor: 5.157

7.  The concentration dependence of the oxygen affinity of haemoglobin S.

Authors:  A May; E R Huehns
Journal:  Br J Haematol       Date:  1975-07       Impact factor: 6.998

8.  Mechanism of anion transport in red blood cells: role of membrane proteins.

Authors:  A Rothstein; Z I Cabantchik; P Knauf
Journal:  Fed Proc       Date:  1976-01

9.  Pyridoxal compounds as specific reagents for the alpha and beta N-termini of hemoglobin.

Authors:  R E Benesch; S Yung; T Suzuki; C Bauer; R Benesch
Journal:  Proc Natl Acad Sci U S A       Date:  1973-09       Impact factor: 11.205

10.  5'-deoxypyridoxal as a potential anti-sickling agent.

Authors:  R Benesch; R E Benesch; R Edalji; T Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

View more
  1 in total

1.  FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.

Authors:  Archana Shrestha; Mengna Chi; Kimberly Wagner; Astha Malik; Jennifer Korpik; Adam Drake; Keertik Fulzele; Sylvie Guichard; Punam Malik
Journal:  Blood Adv       Date:  2021-05-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.